A5074404084- Radiopharmaceutical Chemistry and Applications
- Medical Imaging Techniques and Applications
- Advanced Radiotherapy Techniques
- Radiation Therapy and Dosimetry
- Advanced biosensing and bioanalysis techniques
- DNA Repair Mechanisms
- RNA Interference and Gene Delivery
- Esophageal Cancer Research and Treatment
- DNA and Nucleic Acid Chemistry
- Breast Cancer Treatment Studies
- HER2/EGFR in Cancer Research
- Radiomics and Machine Learning in Medical Imaging
- Monoclonal and Polyclonal Antibodies Research
- Chemical Reactions and Isotopes
- Nanoparticle-Based Drug Delivery
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Cancer, Hypoxia, and Metabolism
- Ultrasound and Hyperthermia Applications
- Nanoplatforms for cancer theranostics
- RNA modifications and cancer
- Neuroblastoma Research and Treatments
- Cancer-related Molecular Pathways
- Hepatocellular Carcinoma Treatment and Prognosis
- Tracheal and airway disorders
University of Oxford
2016-2025
Churchill Hospital
2000-2025
Harvard University
2002-2023
CRUK/MRC Oxford Institute for Radiation Oncology
2014-2023
Mass General Brigham
2023
Medical Research Council
2012-2021
Science Oxford
2010-2020
Oxford University Hospitals NHS Trust
2019-2020
Cancer Research UK
2012-2019
Anglo-Norman Text Society
2016
Most women with breast cancer who undergo breast-conserving surgery receive whole-breast irradiation. We examined whether the addition of regional nodal irradiation to improved outcomes.
Combined radiochemotherapy is the currently used therapy for locally advanced pancreatic ductal adenocarcinoma (PDAC), but normal tissue toxicity limits its application. Here we test hypothesis that inhibition of ATR (ATM-Rad3-related) could increase sensitivity cancer cells to radiation or chemotherapy without affecting cells. We tested VE-822, an inhibitor, in vitro and vivo radiosensitization. Chk1 phosphorylation was indicate activity, γH2AX 53BP1 foci as evidence DNA damage Rad51...
LBA1003 Background: Randomized trials have demonstrated that locoregional radiation after mastectomy reduces recurrence and improves overall survival (OS) in women with node positive breast cancer treated adjuvant systemic therapy. MA.20 evaluated the addition of regional nodal irradiation (RNI) to whole (WBI) following conserving surgery (BCS). Methods: Women high risk node-negative or node-positive BCS chemotherapy and/or endocrine therapy were stratified by nodes, axillary nodes removed,...
The cytotoxicity and tumor-targeting properties of the anti-HER2/neu monoclonal antibody trastuzumab modified with peptides (CGYGPKKKRKVGG) harboring nuclear localization sequence ([NLS] italicized) simian virus 40 large T-antigen radiolabeled (111)In were evaluated.Trastuzumab was derivatized sulfosuccinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (sulfo-SMCC) for reaction NLS-peptides labeled using diethylenetriaminepentaacetic acid (DTPA). immunoreactivity (111)In-NLS-trastuzumab...
Abstract Background Radiopharmaceutical therapy (RPT) has gained notable attention for its potential in treating difficult cancers, with [ 177 Lu]Lu‐DOTATATE being a example. However, the radiobiology of RPT is less understood compared to external beam radiotherapy (EBRT), and dosimetry protocols are not standardized. Organ dose limits tumor dose‐response correlations often based on radiobiologically motivated equieffective doses (EQDX). On top absorbed dose, these measures also functions...
PURPOSE: To assess the risk of fatal and nonfatal myocardial infarction (MI) after breast-conserving surgery (BCS) radiation therapy (RT) for left-sided breast cancer. PATIENTS AND METHODS: A hospital-based retrospective cohort linkage study all cancer patients registered at Princess Margaret Hospital (PMH), Toronto, Canada, between 1982 1988 who were treated with postlumpectomy RT was performed. Available identifiers linked to two province-wide health files: Canadian Institute Health...
Background Breast cancer is the most common malignancy among women worldwide in terms of incidence and mortality. About 10% North American will be diagnosed with breast during their lifetime 20% those die disease. a heterogeneous disease biomarkers able to correctly classify patients into prognostic groups are needed better tailor treatment options improve outcomes. One powerful method used for biomarker discovery sample screening mass spectrometry, as it allows direct comparison protein...
Effective chemotherapeutics for primary systemic tumors have limited access to brain metastases because of the blood–brain barrier (BBB). The aim this study was develop a strategy specifically permeabilizing BBB at sites cerebral metastases. BALB/c mice were injected intracardially induce After metastasis induction, either tumor necrosis factor (TNF) or lymphotoxin (LT) administered intravenously, and 2 24 hours later gadolinium- diethylenetriaminepentaacetic acid, horseradish peroxidase,...
Purpose Radiolabeled antibodies and peptides hold promise for molecular radiotherapy but are often limited by a low payload resulting in inadequate delivery of radioactivity to tumour tissue and, therefore, modest therapeutic effect. We developed facile synthetic method radiolabeling indium-111 (111In) epidermal growth factor (EGF)-gold nanoparticles (111In-EGF-Au NP) with high payload.Materials methods EGF-Au NP were prepared via an interaction between gold the disulphide bonds EGF...
EGFR-targeted PLGA nanoparticles co-deliver the Auger electron emitter<sup>111</sup>In and a ruthenium(<sc>ii</sc>) radiosensitizer for combined therapeutic effects.
Abstract Background Non-toxic approaches to enhance radiotherapy outcomes are beneficial, particularly in ageing populations. Based on preclinical findings showing that high-fibre diets sensitised bladder tumours irradiation by modifying the gut microbiota, along with clinical evidence of prebiotics enhancing anti-cancer immunity, we hypothesised dietary fibre and its microbiota modification can radiosensitise via secretion metabolites and/or immunomodulation. We investigated efficacy...
There have been a series of reports on the association genetic polymorphism at cytochrome P450 CYP2D6 gene locus with cancer susceptibility. Many these remained contradictory either because small numbers patients studied or limitations and controversy surrounding pharmacokinetic assay used to identify affected individuals (poor metabolizers; PMs). We recently developed DNA-based that will allow unequivocal identification poor metabolizers applied this study 1635 different forms cancer. Out...